^
Association details:
| Biomarker: | EGFR exon 20 insertion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Exkivity (mobocertinib) (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Mobocertinib and bevacizumab for amivantamab-refractory lung cancer with EGFR exon 20 insertion mutation: A case report
Published date:
11/07/2023
Excerpt:
We report a case of a patient with EGFR Exon 20-mutated NSCLC who had primary resistance to amivantamab but were successfully treated by combining therapy of another EGFR Exon 20 insertion-specific targeted drug mobocertinib and bevacizumab.
DOI:
https://doi.org/10.1016/j.jtocrr.2023.100600
